EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis

Feng-Yun Zheng, Ya-Yin Tan, Jia-Jun Zhou

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1328 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Feng-Yun Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blood Purification Centre, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China. Hauptthemen laut MEDLINE: Calcium, Hyperparathyroidism, Secondary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study was designed to compare the beneficial effects of paricalcitol combined with or without cinacalcet on calcium and phosphorus metabolism in patients undergoing maintenance hemodialysis (MHD). A total of 140 patients who received MHD in our hospital from March 2021 to March 2022 were randomly divided into a control group (intravenous paricalcitol, n = 70) and a test group (intravenous paricalcitol combined with oral cinacalcet, n = 70). Clinical baseline data and relevant laboratory parameters before treatment were compared. Additionally, calcium, phosphorus, intact parathyroid hormone in serum were measured and compared between the 2 groups before treatment and 1, 2, 3, 4, 5, 6, 9, 10, and 12 months after treatment. As a result, comparison before treatment demonstrated no significant difference in baseline data such as age, sex, and most laboratory parameters between the 2 groups ( P > .05), but there was a significant difference in mean corpuscular volume ( P < .001). The serum phosphorus level decreased and calcium level increased significantly in the 2 groups after treatment, while the intact parathyroid hormone level showed no significant change within 12 months of treatment ( P > .05). In addition, the combined treatment for 6‐12 months caused a much lower phosphorus level ( P < .05) and higher calcium level ( P < .05) than the treatment with paricalcitol alone, and the difference increased with the extension of treatment time. Collectively, paricalcitol combined with cinacalcet, which is more effective than paricalcitol alone, has a positive effect on calcium and phosphorus metabolism in patients receiving MHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalciumHyperparathyroidism, SecondaryHumansCinacalcetRenal DialysisParathyroid HormonePhosphorusErgocalciferols

Stichwörter der Autor:innen

calcium and phosphorus metabolismcinacalcetmaintenance hemodialysisparicalcitol

Substanzen

CinacalcetCalciumParathyroid HormonePhosphorusparicalcitolErgocalciferols

Autor:innen und Institutionen

  • Blood Purification Centre, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China.

Zitieren

APA

Zheng, F. Y., Tan, Y. Y., & Zhou, J. J. (2024). Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1328

Vancouver

Zheng FY, Tan YY, Zhou JJ. Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1328

BibTeX
@article{Zheng2024,
  author = {Zheng, Feng-Yun and Tan, Ya-Yin and Zhou, Jia-Jun},
  title = {Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1328}
}
Kostenlos starten →